Abstract 1119
Background
Clinical features and therapeutic strategies for peritoneal washing cytology- positive (CY+) gastric cancer without gross peritoneal metastasis have not yet been defined. The aim of the study was to evaluate the clinical prognostic impacts of postoperative chemotherapy for treating gastric cancer patients with CY+ without peritoneal metastasis.
Methods
Intraoperative peritoneal washing cytology was performed in 285 patients who underwent curative D2 gastrectomy between April 2004 and May 2016. Of them, 88 patients with CY+ without peritoneal metastasis were included in the study. 64 patients received postoperative chemotherapy, whereas 24 patients underwent surgery only. We combined CY + 64 patients who received postoperative chemotherapy with another cohort of stage II/III gastric cancer patients (n = 819) who received adjuvant chemotherapy, for survival comparison.
Results
The Disease-free survival (DFS) and overall survival (OS) curves were well separated according to stage and CY+ in combined cohort (both, P < 0.001). CY+ gastric cancer patients demonstrated the worst DFS and OS in combined cohort. CY+ gastric cancer patients showed poorer DFS and OS than CY- gastric cancer patients (CY+ vs. CY-, median DFS 10.270 months vs. not reached, P < 0.001; median OS 19.730 vs. 59.400 months, P < 0.001). Postoperative chemotherapy improved DFS and OS compared to surgery only in CY+ patients group (median DFS 11.630 vs. 6.980 months, P < 0.001; median OS 25.500 vs. 12.110 months, P < 0.001). In multivariate analyses in the CY+ patients group, no chemotherapy was the strongest clinical factor for poorer DFS (HR 3.761, P < 0.001) and OS (HR 4.366, P < 0.001).
Conclusions
The prognosis of gastric cancer with CY+ without gross peritoneal metastasis is somewhat different from gastric cancer with overt peritoneal metastasis, and postoperative chemotherapy improves survival outcome in this patient group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract
2444 - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma
Presenter: Emma Ococks
Session: Poster Display session 2
Resources:
Abstract